September 2025
1. ZHANG J, Liu X, Xu Y
   Cardiovascular toxicity risks in treating EGFR-mutated lung cancer.
   BMJ. 2025;390:r1834.
   

   >> Share

   
   
2. MA Z, Cao F, Liao M, Min R, et al
   Cardiovascular adverse events associated with epidermal growth factor receptor tyrosine kinase inhibitors in EGFR-mutated non-small cell lung cancer: systematic review and network meta-analysis.
   BMJ. 2025;390:e082834.
   

   >> Share

   
   June 2025
3. FANG W, Li X, Wang Q, Meng X, et al
   Sacituzumab tirumotecan versus docetaxel for previously treated EGFR-mutated advanced non-small cell lung cancer: multicentre, open label, randomised controlled trial.
   BMJ. 2025;389:e085680.
   

   >> Share

   
   
4. MA X, Li X
   EGFR-mutated non-small cell lung cancer.
   BMJ. 2025;389:r1154.
   

   >> Share

   
   February 2025
5. WELCH HG, Gao W, Wilder FG, Kim SY, et al
   Lung cancer screening in people who have never smoked: lessons from East Asia.
   BMJ. 2025;388:e081674.
   

   >> Share

   
   February 2024
6. HOPKINSON NS
   Smoking and lung cancer-70 long years on.
   BMJ. 2024;384:q443.
   

   >> Share

   
   November 2023
7. TANNE JH
   Expand lung cancer screening to 5 million more people, says American Cancer Society.
   BMJ. 2023;383:p2588.
   

   >> Share

   
   October 2023
8. WISE J
   NICE says there is insufficient evidence to support use of AI for lung cancer diagnosis.
   BMJ. 2023;383:2284.
   

   >> Share

   
   

Free Medical Abstracts
Privacy Policy
Sponsors
Share